EXEL Stock Analysis: Buy, Sell, or Hold?
EXEL - Exelixis Inc
$54.08
0.39 (0.73%)
â˛
5d:
+5.54%
30d:
-2.82%
90d:
+8.92%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When EXEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: EXEL is fairly priced but lacks strong directional signals. At 1.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: EXEL is fairly priced but lacks strong directional signals. At 1.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$83.07
Based on 10.1% avg growth
INTRINSIC VALUE TODAY
$51.58
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EXEL is currently trading at $54.08, which is considered fair relative to its 30-day fair value range of $52.55 to $56.21. The stock's valuation (Forward PE: 13.0) is in line with its historical norms (12.4). At these levels, the market is pricing in 1.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EXEL is in a strong uptrend. The price is approaching resistance at $54.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: EXEL scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EXEL is in a strong uptrend. The price is approaching resistance at $54.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: EXEL scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$52.55 -
$56.21
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Protect Your Profits
Holding EXEL? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($53.00)
- NEUTRAL: Market pricing in 1.5% annual earnings growth - fairly valued
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$52.55 -
$56.21
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$49.97
Resistance Level
$54.68
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.01
Wall Street Target
$53.00
(-2.0%)
Revenue Growth (YoY)
10.6%
Earnings Growth (YoY)
26.2%
Profit Margin
35.3%
Valuation Premium vs History
+1.5% premium
PE vs Historical
13.0 vs 12.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.5%
(market-implied from PE analysis)
1-Year Target
$54.89
(+2%)
2-Year Target
$55.71
(+3%)
3-Year Target
$56.55
(+5%)
3-Yr Target (if PE normalizes)
(PE: 13â12)
PE COMPRESSION
$53.90
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 16.2%)
$130.77
(+142%)
Base:
(SPY PE: 13.0, Growth: 16.2%)
$84.77
(+57%)
Bear:
(PE: 11.1, Growth: 16.2%)
$72.06
(+33%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (17x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 16.88 | Current EPS (TTM): $3.18
Bull Case
$77.20
(+43%)
Analyst growth 30.7%, PE expands to 18.6
Base Case
$70.18
(+30%)
Market implied 30.7%, PE stable at 16.9
Bear Case
$36.51
(-33%)
Severe decline -20.0%, PE contracts to 14.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 23, 2026 11:49 PM ET
Data refreshes hourly during market hours. Next update: 12:49 AM
Data refreshes hourly during market hours. Next update: 12:49 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EXEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$560 | 30 SELL |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
Advanced EXEL Option Strategies
Professional options setups generated by AI based on today's EXEL price and gamma walls.
